Who is sponsoring NCT00471744?

NCT00471744 is sponsored by Ludwig-Maximilians - University of Munich.

What drugs are being tested in NCT00471744?

Interventions in NCT00471744: Treatment with levetiracetam or sulthiame over a six-month period..

What condition does NCT00471744 study?

NCT00471744 studies Epilepsy, Rolandic.

Is NCT00471744 still recruiting?

NCT00471744 is currently terminated. Last updated 28 January 2009.

Last reviewed 2009-01-28 · How we verify

NCT00471744: HEAD

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

HEAD-TO-HEAD Evaluation of the Antiepileptic Drugs Levetiracetam (LEV) vs. Sulthiame (STM) in a German Multi-Centre, Doubleblind Controlled Trial in Children With Benign Epilepsy With Centro-Temporal Spikes

Terminated Phase 3 Last updated 28 January 2009

What this trial tests

Phase 3 trial testing Treatment with levetiracetam or sulthiame over a six-month period. in Epilepsy, Rolandic in 44 participants. Terminated before completion.

Timeline

1 June 2006

1 July 2008

Quick facts

Lead sponsor	Ludwig-Maximilians - University of Munich
Phase	Phase 3
Status	Terminated
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	44
Start date	1 June 2006
Estimated completion	1 July 2008
Sites	1 location across Germany

Drugs / interventions tested

Treatment with levetiracetam or sulthiame over a six-month period. — full drug profile →

Conditions studied

Epilepsy, Rolandic — all drugs for Epilepsy, Rolandic →

Sponsor

Ludwig-Maximilians - University of Munich

Who can join

Adults 6 to 12, any sex, with Epilepsy, Rolandic. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

To evaluate the efficacy of levetiracetam in the treatment of children with BECTS compared to sulthiame
Time frame: 6 months

Sponsor's own description

The investigators hypothesize that Levetiracetam is as effective as Sulthiame in the treatment of children with BECTS. Patients entering the HEAD-Studie are either treated with Leveitracetam or Sulthiame over a 6 months period. Patients are equally randomised to one of the two treatment regimens. Administration of medication as blinded capsules.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Ludwig-Maximilians - University of Munich trials

Trials by the same sponsor.

NCT07514520 — Decision-making, Ethical Consent, and Interactive Dialogue in Ongoing Neurocognitive Decline - DECISION · active not recruiting
NCT07504965 — Dementia-friendly Apothecaries as a Resource for Mental Heath in the Elderly · recruiting
NCT07100548 — A Qualitative Analysis of Youth Responses to Depression Education Delivered on Social Media · completed
NCT07061600 — Enhancing Depression Literacy and Reducing Stigma in Adolescents Through Social Media · NA · completed
NCT06749106 — Plaque Imaging in Routine Care to Detect Intraplaque Hemorrhage · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00471744 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Ludwig-Maximilians - University of Munich
Last refreshed: 28 January 2009

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00471744.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing